// App-Quantinova.ai

524 : A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vilobelimab, an Anti-C5a Monoclonal Antibody, in ANCA-Associated Vasculitis

Researchers

Presenter

  • Peter Merkel

Principal Investigators

  • Bernhard Hellmich

  • Anja Pfaff

  • Carina Müller

  • Elena Startseva

  • David Jayne

Medical Centers

  • University of Pennsylvania, Philadelphia, PA

  • Klinik für Innere Medizin, Rheumatologie & Immunologie, Medius Kliniken, Universität Tübingen, Plochingen, Germany

  • InflaRx GmbH, Jena, Germany

  • Metronomia Clinical Research GmbH, Munich, Germany

  • University of Cambridge, Cambridge, United Kingdom

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Genetic Disorder

Disease

  • Anti-neutrophil cytoplasmic antibody-associated vasculitis

Biomarkers

  • Cytochrome C

Drug/Treatment

  • Glucocorticoid

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Prospective

  • Controlled

Phase

  • II

Study Id's

  • NCT03895801

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved